Testing a new skin disease treatment in people with moderate to severe psoriasis

Plain-English translation of NCT06696417 on ClinicalTrials.gov ↗ · Source last updated May 2025 · Translation generated June 2026 · How we translate trials

What is this trial?

This trial is testing vunakizumab, an injectable medication designed to treat moderate to severe psoriasis by targeting a specific protein in the body that drives psoriasis. Researchers want to understand how well and safely this medication works in a large group of Chinese patients who have never tried biologic treatments before. The trial will also look at how the medication affects specific areas of the skin, quality of life, and mental health.

While this medication has already been approved and used, there is not yet enough safety and effectiveness data from large groups of patients in China. This trial will help doctors better understand how this treatment works for Chinese patients and how it can improve not just skin symptoms but also patients' overall well-being.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with moderate to severe plaque psoriasis
you have never received biologic medications for psoriasis before
you are willing and able to follow the study protocol and complete all required visits
you can communicate clearly with the research team and understand the study requirements

You likely don't qualify if…

you have previously taken any biologic medications (such as TNF-inhibitors, IL-17 inhibitors, or IL-23 inhibitors)
you have a severe allergic reaction to this medication or its ingredients
you have an active serious infection like tuberculosis, active hepatitis, or active cancer
you are pregnant or planning to become pregnant, or are unwilling to use effective birth control during the study and for 20 weeks after your last dose
you have other medical conditions that would prevent you from safely completing the study

What participation looks like

As a participant, you would receive vunakizumab injections as prescribed by the research team. You would attend multiple visits to have your psoriasis evaluated, answer questions about your skin symptoms and quality of life, and potentially provide information about your mental health and overall well-being. The study involves about 1,500 patients across multiple centers in China, and your doctors will monitor you carefully throughout treatment to ensure the medication is working and is safe for you.

AI-generated summary from trial data · Jun 17, 2026 · Not medical advice

Trial locations(1 site)

China

The First Hospital of China Medical University, Shenyang, Liaoning